Varian Announces First Participant Treated in GENESIS II Clinical Trial of Genicular Artery Embolization for Knee Osteoarthritis
Excerpt from the Press Release:
PALO ALTO, Calif., Nov. 17, 2022 /PRNewswire/ — Varian, a Siemens Healthineers company, announced today that the first trial participant has been treated as part of GENESIS II (Genicular artEry embolisatioN in patiEnts with oSteoarthrItiS of the knee), a study of Embozene® microspheres for genicular artery embolization (GAE) as treatment of mild to moderate knee osteoarthritis. GENESIS II is the largest randomized clinical trial of GAE to assess pain relief from this debilitating condition.
GENESIS II is being conducted at the University Department of Radiology, Royal Berkshire NHS Foundation Trust, in Reading, UK. The trial targets mild to moderate osteoarthritis (OA) of the knee joint, a common condition and a leading cause of chronic disability. GAE is a minimally invasive procedure in which a small catheter is advanced into the genicular arteries, the small blood vessels that supply the knee joint and contribute to the inflammatory process. The Embozene microspheres are delivered through the catheter to reduce the blood supply to the areas of greatest inflammation in the knee with the goal of reducing pain.
In the GENESIS II clinical trial, patients with knee osteoarthritis will either receive treatment with the Embozene microspheres or a sham control; they have the option to receive Embozene treatment later in the clinical trial.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?